Dual-Energy CT in Patients Treated with Anti-Angiogenic Agents for Non-Small Cell Lung Cancer: New Method of Monitoring Tumor Response?

다국어 초록 (Multilingual Abstract)

Objective: To evaluate tumor responses in patients treated with anti-angiogenic agents for non-small cell lung cancer (NSCLC) by assessing intratumoral changes using a dual-energy CT (DECT) (based on Choi’s criteria) and to compare it to traditional Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Materials and Methods: Ten NSCLC patients treated with bevacizumab underwent DECT. Tumor responses to anti-angiogenic therapy were assessed and compared with the baseline CT results using both RECIST (size changes only) and Choi’s criteria (reflecting net tumor enhancement). Kappa statistics was used to evaluate agreements between tumor responses assessed by RECIST and Choi’s criteria.
Results: The weighted κ value for the comparison of tumor responses between the RECIST and Choi’s criteria was 0.72. Of 31 target lesions (21 solid nodules, 8 lymph nodes, and two ground-glass opacity nodules [GGNs]), five lesions (16%) showed discordant responses between RECIST and Choi’s criteria. Iodine-enhanced images allowed for a distinction between tumor enhancement and hemorrhagic response (detected in 14% [4 of 29, excluding GGNs] of target lesions on virtual nonenhanced images).
Conclusion: DECT may serve as a useful tool for response evaluation after anti-angiogenic treatment in NSCLC patients by providing information on the net enhancement of target lesions without obtaining non-enhanced images.

다국어 초록 (Multilingual Abstract)

Objective: To evaluate tumor responses in patients treated with anti-angiogenic agents for non-small cell lung cancer (NSCLC) by assessing intratumoral changes using a dual-energy CT (DECT) (based on Choi’s criteria) and to compare it to traditional Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Materials and Methods: Ten NSCLC patients treated with bevacizumab underwent DECT. Tumor responses to anti-angiogenic therapy were assessed and compared with the baseline CT results using both RECIST (size changes only) and Choi’s criteria (reflecting net tumor enhancement). Kappa statistics was used to evaluate agreements between tumor responses assessed by RECIST and Choi’s criteria.
Results: The weighted κ value for the comparison of tumor responses between the RECIST and Choi’s criteria was 0.72. Of 31 target lesions (21 solid nodules, 8 lymph nodes, and two ground-glass opacity nodules [GGNs]), five lesions (16%) showed discordant responses between RECIST and Choi’s criteria. Iodine-enhanced images allowed for a distinction between tumor enhancement and hemorrhagic response (detected in 14% [4 of 29, excluding GGNs] of target lesions on virtual nonenhanced images).
Conclusion: DECT may serve as a useful tool for response evaluation after anti-angiogenic treatment in NSCLC patients by providing information on the net enhancement of target lesions without obtaining non-enhanced images.

참고문헌 (Reference)

1 Barrett T, "Virtual unenhanced second generation dual-source CT of the liver: is it time to discard the conventional unenhanced phase?" 81 : 1438-1445, 2012

2 Crabb SJ, "Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer" 27 : 404-410, 2009

3 Pirker R, "Targeted therapies in lung cancer" 15 : 188-206, 2009

4 Sandler AB, "Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab" 27 : 1405-1412, 2009

5 Johnson DH, "Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer" 22 : 2184-2191, 2004

6 Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)" 45 : 228-247, 2009

7 이호연, "New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy" ELSEVIER IRELAND LTD 73 (73): 63-69, 201107

8 이호연, "Molecularly Targeted Therapy Using Bevacizumab for Non-Small Cell Lung Cancer: a Pilot Study for the New CT Response Criteria" 대한영상의학회 11 (11): 618-626, 2010

9 Johnson TR, "Material differentiation by dual energy CT: initial experience" 17 : 1510-1517, 2007

10 Schmid-Bindert G, "Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT?" 22 : 93-103, 2012

11 Hansell DM, "Fleischner Society: glossary of terms for thoracic imaging" 246 : 697-722, 2008

12 Gupta R, "Evaluation of dual-energy CT for differentiating intracerebral hemorrhage from iodinated contrast material staining" 257 : 205-211, 2010

13 Coursey CA, "Dual-energy multidetector CT: how does it work, what can it tell us, and when can we use it in abdominopelvic imaging?" 30 : 1037-1055, 2010

14 이현주, "Dual-energy CT: Clinical applications in various pulmonary diseases" Radiological Society of North America, Inc. 30 (30): 685-698, 201005

15 Graser A, "Dual-energy CT in patients suspected of having renal masses: can virtual nonenhanced images replace true nonenhanced images?" 252 : 433-440, 2009

16 Schenzle JC, "Dual energy CT of the chest: how about the dose?" 45 : 347-353, 2010

17 Choi H, "Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria" 25 : 1753-1759, 2007

18 채은진, "Clinical Utility of Dual-Energy CT in the Evaluation of Solitary Pulmonary Nodules: Initial Experience" RADIOLOGICAL SOC NORTH AMERICA 249 : 671-681, 200811

19 Ling D, "CT demonstration of bilateral adrenal hemorrhage" 141 : 307-308, 1983

20 Bertino EM, "Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer" 70 : 233-246, 2010